MUC5AC and COVID-19: MUC5AC is overproduced in COPD and asthmatic patients (22, 28); however, the majority of these patients are at higher risk of complications from COVID-19 (24, 25), suggesting that MUC5AC alone cannot block SARS-CoV-2 infection.